FOLD

NEUTRALM&A

Amicus Therapeutics, Inc.

2026-03-18

Price

$14.37

+0.00%

Score7.8Priority

Signals6/8 DNA2/13 Act · 1/4 Risk

SentimentNEUTRALScore: 6

Volume0.8xvs 20d avg

Analysis

FOLD's price action and extremely low volatility are entirely dictated by its pending $14.50 per share all-cash acquisition by BioMarin, announced in December 2025. The technical signals—such as QUIET_STORM and STEADY_CLIMB—along with a microscopic 1.7% annualized volatility, perfectly reflect a classic merger arbitrage scenario where the stock is pinned just below the buyout price. In the current RISK_OFF geopolitical regime, FOLD is acting as a non-correlated safe haven, easily outperforming the SPY due to the hard floor provided by the definitive merger agreement.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSBOLLINGER SQUEEZEPERFECT STACKSELLER FATIGUEBARGAIN HUNTERWEAK FINISH

Key Takeaways

Actionable Thesis: FOLD is a pure merger arbitrage play offering a tight ~0.9% gross spread up to the $14.50 BioMarin cash offer, acting as a cash proxy in a turbulent market.
Key Risk: The primary downside risk is a deal collapse due to unforeseen antitrust hurdles or regulatory blocks, which would likely send shares plunging back toward pre-deal levels of ~$11.
What to Watch: Monitor regulatory filings, FTC commentary, and BioMarin's corporate updates to ensure the acquisition remains on track for its scheduled Q2 2026 closing.

← Back to 2026-03-18 View Full FOLD History →Yahoo Finance &nearr;